Craug Elmets
University of Alabama at Birmingham
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Craug Elmets as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:10 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04091022 · Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin CancerUniversity of Alabama at Birmingham · completed · Non-melanoma Skin Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Topical Chemoprevention of Skin Cancer BiomarkersR01CA193885 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Craig A Elmets · fiscal years 2016 to 2022Named on NCT04091022
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:10 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.Lancet Oncol · 2018563 citationsRCR 19.4
- Cutaneous photoprotection from ultraviolet injury by green tea polyphenols.J Am Acad Dermatol · 2001225 citationsRCR 7.3
- Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.J Natl Cancer Inst · 2010183 citationsRCR 5.2
- Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.Vaccine · 2005181 citationsRCR 4.2
- Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes: two-year results evaluating tumor response and cosmetic outcomes.Arch Dermatol · 200475 citationsRCR 2.7
- Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.J Drugs Dermatol · 200857 citationsRCR 2.4
- Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus.J Dermatolog Treat · 200537 citationsRCR 1.3
- A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma.J Am Acad Dermatol · 200131 citationsRCR 0.9
- A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology.Cancer Prev Res (Phila) · 201423 citationsRCR 0.7
- 18 citationsRCR 1.1